"After my diagnosis I thought I could use my experience in business to promote MPN research and create scientific activity where very little had previously occurred." - Robert Rosen, Chairman, MPN Research Foundation

Mission

The MPN Research Foundation has a single goal: to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).



Diagnosed with polycythemia vera in 1997, Chicago business man Robert Rosen was shocked to learn that little research was being conducted on PV, ET, and MF, and that there was no advocacy groups working to assist people with these rare blood cancers. In 1999, Rosen, Bob Pritzker and two other MPN patients established the MPN Research Foundation (at the time known as MPD Foundation) as a way to change all that.

Founded by patients, for patients, terms on every research grant are negotiated to maximize the dollars invested in actual research. We only fund projects relevant to PV, ET, and MF and are always mindful of selecting projects that will accelerate understanding of the MPNs in hopes of finding a cure.

To date, the Foundation has awarded approximately nine million dollars for MPN research. While our priority remains on funding innovative and accountable research, we have also increased our efforts to educate and empower the MPN community of patients, family members, doctors and researchers. We offer a free newsletter, assist support groups, and work with other organizations to educate patients.

To join our mailing list, please click here or contact us now.

 

Become a member

Free membership includes MPN Update newsletter, alerts, RFP announcements and more.

Join today

 

 

 

Your donation goes a long way.

Learn more about how you can help support the MPN Research Foundation and the impact your contributions can make.

Donate Now
 
 
 

Connect with Us

MPN Research Foundation wants to hear from you. Connect with us through our social networks or send us an email.

Email Facebook Twitter LinkedIn